We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » RIGImmune Acquires Subintro and its Nasal Drug Delivery System
RIGImmune Acquires Subintro and its Nasal Drug Delivery System
RIGImmune announced its acquisition of Subintro, a move the company says is focused on development of intranasal delivery of RIGImmune’s stem-loop RNA antivirals and vaccines to treat and prevent respiratory diseases caused by RNA viruses such as COVID-19, influenza, RSV and rhinoviruses.